The standard treatment options in low-and-middle income countries like Ethiopia is usually nothing.
The next best option are cobbled together respiratory devices.
Treatment options may require more infrastructural support, space, and come at a cost that is too high in LMIC and poorer pockets of the United States.
Side effects for ventilators and CPAP stem from their use of cold dry air as well as the requirement to maintain pressure to deliver air to patients.
We have a have developed a final prototype of a low-cost self-sterilizing humidified high-flow nasal cannula.
Our patented device oxygenates, warms, humidifies, and sterilizes air before it is delivered in an all-in-one mobile enclosure.
Our device is comparable to an already approved FDA device.
There is a sizable global market for these devices and recent exits have been favorable.